Milestone Pharmaceuticals Management
Management criteria checks 3/4
Milestone Pharmaceuticals' CEO is Joe Oliveto, appointed in Mar 2017, has a tenure of 7.17 years. total yearly compensation is $2.97M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $469.65K. The average tenure of the management team and the board of directors is 4.2 years and 5.9 years respectively.
Key information
Joe Oliveto
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 19.7% |
| CEO tenure | 7.2yrs |
| CEO ownership | 0.5% |
| Management average tenure | 4.2yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
Sep 13
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Mar 07We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Oct 15We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
Jun 24We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
Feb 25We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Aug 25Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
Apr 02What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
Jan 15First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT
Nov 18Milestone Pharmaceuticals EPS beats by $0.09
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$60m |
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$3m | US$584k | -US$58m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$62m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$4m | US$509k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$470k | -US$50m |
| Sep 30 2020 | n/a | n/a | -US$60m |
| Jun 30 2020 | n/a | n/a | -US$60m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$785k | US$458k | -US$55m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$29m |
| Dec 31 2018 | US$1m | US$360k | -US$23m |
| Dec 31 2017 | US$851k | US$364k | -US$8m |
Compensation vs Market: Joe's total compensation ($USD2.97M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
CEO
Joe Oliveto (55 yo)
7.2yrs
Tenure
US$2,965,827
Compensation
Mr. Joseph G. Oliveto, also known as Joe, M.B.A. has been Chief Executive Officer and President of Milestone Pharmaceuticals Inc. March 2017 and has been its Director since July 2017. Mr. Oliveto served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 7.2yrs | US$2.97m | 0.45% $ 469.7k | |
| CFO & Executive VP of Corporate Development | 4.7yrs | US$1.32m | 0.0065% $ 6.7k | |
| Chief Medical Officer | 2.3yrs | US$2.05m | 0.016% $ 16.5k | |
| Founder | no data | no data | no data | |
| Chief Operating Officer | 4.2yrs | no data | no data | |
| Vice President of Communications | less than a year | no data | no data | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | 4.3yrs | no data | no data | |
| SVP of Regulatory Affairs and Quality Management | no data | no data | no data | |
| VP & Head of Medical Affairs | 1.8yrs | no data | no data |
4.2yrs
Average Tenure
58yo
Average Age
Experienced Management: MIST's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 6.8yrs | US$2.97m | 0.45% $ 469.7k | |
| Founder | 4.3yrs | no data | no data | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Observer | 6.8yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 8.9yrs | US$187.74k | 0.023% $ 23.3k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 5.1yrs | US$187.74k | 0.024% $ 24.7k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 3.6yrs | US$215.24k | 0.024% $ 24.7k |
5.9yrs
Average Tenure
66.5yo
Average Age
Experienced Board: MIST's board of directors are considered experienced (5.9 years average tenure).